LAG-3 drugs for Melanoma
2 tracked LAG-3 drugs in the Melanoma race. The class explanation lives on the LAG-3 page; the full indication pipeline across every mechanism is on the Melanoma page.
1 approved / phase 41 Phase 3
Head-to-head evidence: Fianlimab vs Relatlimab